A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

NCT04033926 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Polymyositis
Dermatomyositis

Interventions

DRUG: KZR-616
DRUG: Placebo

Sponsor

Kezar Life Sciences, Inc.